What does Penam Laboratories Limited manufacture?

Penam Laboratories Limited is a New Delhi-based pharmaceutical company incorporated in 1989 that manufactures Active Pharmaceutical Ingredients (APIs) and finished pharmaceutical formulations. The company serves the domestic pharmaceutical market and potentially exports APIs to international buyers.

When was Penam Laboratories Limited incorporated?

Penam Laboratories Limited was incorporated in 1989 and is registered in New Delhi with CIN U24231DL1989PLC037287.

Is Penam Laboratories Limited listed on any stock exchange?

No. Penam Laboratories Limited is an unlisted company. Its shares are not traded on BSE or NSE and are available only through the unlisted grey market.

What is Penam Laboratories' website?

Penam Laboratories Limited's website is available at http://www.penam.in, where further product and company information may be found.

What is the CIN of Penam Laboratories Limited?

The Corporate Identification Number (CIN) of Penam Laboratories Limited is U24231DL1989PLC037287.

How do I buy Penam Laboratories unlisted shares here?

Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.

Who am I actually transacting with?

You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.

How do I pay, and is there a payment gateway?

Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

How long does settlement take?

After you accept an allocation, you have a short window to pay (typically 2 days). Once payment is verified, shares are usually credited to your demat within 2–3 business days, subject to depository timelines and any company-level restrictions. Timeframes are typical, not guaranteed.

There are no separate platform fee lines and no GST on the transfer — the desk's margin is built into the buy/sell price you're quoted. The only statutory add-on on a purchase is stamp duty on the consideration, shown transparently in your cost breakdown.

Is there a minimum ticket size for Penam Laboratories?

Minimums vary by company and depend on the lot the desk can source. Raise an enquiry and the desk will confirm the available quantity and the minimum for that name.

What KYC do I need, and do I need a demat account?

You'll share your demat details when you enquire so we can settle directly. Full KYC — PAN and a client-master / demat statement — is required before the transfer step, when shares actually change hands. Yes, you need an active demat account to hold unlisted shares.

Are there lock-ins on unlisted or pre-IPO shares?

Some shares carry statutory or company-imposed lock-ins — for example, a post-listing lock-in on pre-IPO stock — and transfers can be subject to the company's articles or approvals. Where a lock-in applies, we'll flag it before you commit.

How do I sell Penam Laboratories shares I already hold?

Raise a sell enquiry with the company, quantity and your target price. The desk confirms a buying price, you transfer your shares into the desk's demat, and once the credit is verified we pay you out by bank transfer to your registered account. The desk never pays out before your shares are received.

Unlisted shares are illiquid, may be hard or impossible to sell, and are not covered by exchange settlement guarantees or investor-protection funds. Pricing is indicative, not live. Read the full Risk Disclosure before you enquire, and invest only what you can afford to lock away.

Penam Laboratories Unlisted Share Price | Buy Penam Laboratories Pre-IPO Shares — wisefolio

Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Talk to us

Penam Laboratories Unlisted Share Price | Buy Penam Laboratories Pre-IPO Shares — wisefolio | wisefolio

Investment Thesis

Penam Laboratories Limited is a New Delhi-based pharmaceutical API and formulations company with over 35 years of operating history. The company operates in a sector with strong policy tailwinds from India's API self-reliance push, but faces structural challenges from the scale advantages of larger competitors. The absence of public financial disclosures makes it impossible to assess the company's financial health, profitability, or growth trajectory. At an indicative price of INR 955, investors must conduct thorough due diligence directly with the company before considering any exposure.

Pros

Over three decades of operational history in pharmaceutical API and formulations manufacturing since 1989
New Delhi headquarters offers proximity to regulatory bodies like CDSCO and facilitates institutional and government procurement channels
Pharmaceutical API manufacturing is a high-skill, regulated business with significant barriers to entry including GMP certifications and regulatory approvals
APIs are critical inputs to the broader pharmaceutical supply chain, ensuring steady industrial demand
India's pharmaceutical export growth and 'Atmanirbhar Bharat' push for domestic API production creates a favourable policy environment for established API manufacturers

Cons

Unlisted status with very limited publicly available financial disclosures makes investment analysis difficult
Smaller API manufacturers face intense competition from larger players like Divi's Laboratories, Laurus Labs, and IPCA Laboratories with far greater scale
API manufacturing requires continuous capex in plant upgrades and regulatory compliance to maintain quality certifications
No publicly disclosed revenue, profitability, or debt metrics are available for independent assessment
Key-person and succession risk in smaller family-run pharmaceutical companies is typically elevated

Business Segments

Active Pharmaceutical Ingredients (APIs)

Manufacturing of bulk active pharmaceutical ingredients supplied to formulations manufacturers in India and potentially for export

Pharmaceutical Formulations

Production of finished dosage forms including tablets, capsules, and injectables for the domestic pharmaceutical market

Revenue Model

Penam Laboratories generates revenue through the sale of pharmaceutical APIs to formulations manufacturers and through sales of finished pharmaceutical products to institutional buyers, distributors, and the domestic retail pharma trade. API pricing is influenced by raw material costs (intermediates, solvents) and competitive market dynamics.

Detailed Analysis

Growth outlookExpansion plans, industry tailwinds & headwinds12

Growth Plans

India's PLI scheme for bulk drugs incentivising domestic API manufacturing and reducing import dependency

Growing global demand for Indian pharmaceutical APIs driven by cost competitiveness

Potential regulatory approvals (US FDA, EU GMP) unlocking export market access

Consolidation in the Indian API sector creating acquisition opportunities for well-positioned small players

Industry Tailwinds

Recent Developments

India API sector policy support

The Government of India's Production Linked Incentive (PLI) scheme for bulk drugs and APIs continues to create a favourable policy environment for domestic API manufacturers. Companies like Penam Laboratories operating in the API space benefit from increased domestic demand for locally manufactured APIs as pharma companies seek to reduce import dependency.

2023-04

Continued unlisted operations

Penam Laboratories Limited continues to operate as an unlisted pharmaceutical company in New Delhi. No material corporate actions or public announcements have been reported.

2024-01

Comparable Companies

CompanyTypeTickerMkt Cap

Divi's Laboratories LimitedListedDIVISLAB~₹1,10,000 Cr

IPCA Laboratories LimitedListedIPCALAB~₹25,000 Cr

Laurus Labs LimitedListedLAURUSLABS~₹30,000 Cr

Divi's Laboratories LimitedListed

DIVISLAB · ~₹1,10,000 Cr

Frequently Asked Questions

About Penam Laboratories

Penam Laboratories Limited is a Delhi-based pharmaceutical manufacturer incorporated in 1989, specializing in Beta Lactam group of antibiotic Bulk Drugs (APIs) and pharmaceutical formulations. With CIN U24231DL1989PLC037287, the company has established itself as one of India's recognized producers in the specialized and technically demanding beta-lactam antibiotic space. Beta-lactam antibiotics — which include penicillins, cephalosporins, and carbapenems — form the backbone of global antibacterial therapy and represent one of the largest segments in pharmaceutical APIs globally. Penam Laboratories' specialization in this category positions it in a high-value, regulated manufacturing niche that requires strict quality controls and specialized infrastructure to prevent cross-contamination. Founded over three decades ago, Penam Laboratories has developed manufacturing expertise in producing beta-lactam APIs and converting them into finished formulations including dry syrups, capsules, and injectable products. The company operates under the brand 'Penam' and markets its products to pharmaceutical companies, hospitals, and distribution networks. The company's registered address is in Central Delhi, while its manufacturing operations (per its website at penam.in) encompass dedicated beta-lactam manufacturing facilities that comply with regulatory standards. The company last held its AGM in December 2023 and filed its balance sheet for FY2023, confirming active operations. Penam Laboratories operates in a sector with significant barriers to entry — beta-lactam manufacturing requires dedicated facilities, complex regulatory approvals, and specialized technical expertise. This creates a natural moat for established players like Penam. The company sells both APIs to bulk pharmaceutical buyers and finished formulations to healthcare providers, creating dual revenue streams. The pharma group has related entities including Penam Pharmaceuticals Private Limited and Penam Biosciences Private Limited, suggesting a family of companies with broader pharmaceutical manufacturing ambitions.

Key Milestones

Common questions about unlisted shares

How do I buy Penam Laboratories unlisted shares here?
Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.
Who am I actually transacting with?
You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.
How do I pay, and is there a payment gateway?

Penam Laboratories Limited

How settlement works

Get price alerts for Penam Laboratories Limited

Discuss Penam Laboratories

Similar companies

Other ways to invest